Concerning 'Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease' by Nascimbeni et al

Gaucher disease (GD) has received great attention in the past years in the realm of hepatology research. It is a multisystem disorder caused by lysosomal accumulation and dysfunction, and its classical description is that of anaemia, thrombocytopenia, hepatosplenomegaly, bone disease, and neurological involvement. Recently, however, as patient cohorts are treated long-term with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT), other hepatic manifestations such as steatosis and fibrosis started to emerge, as appropriately reviewed by Nascimbeni and colleagues.